Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume N/A
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.

Phone: 212-426-7040
Woodman7
Woodman7 Jul. 14 at 10:12 AM
0 · Reply
degeneratetrader23
degeneratetrader23 Jul. 13 at 2:39 PM
$PSNL $ARKG, $TEM, and $NTRA are all red. This is mooning!
0 · Reply
madnessofcrowds
madnessofcrowds Jul. 10 at 8:42 PM
$ARKG locked in gains for about 25% of my position here. it's going much higher but wouldn't mind a cheaper entry.
0 · Reply
CactusPicksEm
CactusPicksEm Jul. 9 at 1:58 PM
$ARKG STO 8/21 50C for a 1.25 credit against my lot
0 · Reply
B2iDigital
B2iDigital Jul. 8 at 11:59 PM
eXoZymes (Nasdaq: $EXOZ ) makes its case for cell-free biomanufacturing, the approach it says sidesteps where whole-cell synthetic biology has repeatedly failed to scale. Whole-cell synthetic biology has a long record of stalling at scale. In a Webull webinar, eXoZymes Chief Commercial Officer Damien Perriman laid out why the company removed the cell from the equation entirely. eXoZymes Inc. is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/exozymes-1 "Engineered cells have become a boulevard of broken dreams on Wall Street, and eXoZymes found a way to navigate around this problem," said Damien Perryman, Chief Commercial Officer of eXoZymes. In the webinar, Perryman also covered: • Cells evolved to survive, not to manufacture, so whole-cell systems carry biological noise, toxicity limits, and regulatory complexity into production • eXoZymes isolates the enzymes, engineers them with AI, and runs them outside the cell to produce target molecules cleanly and at scale • The result behaves more like precision chemistry than a biological production system, inspired by biology's own catalysts Watch the full webinar: youtube.com/watch?v=OmH3TaaMT20&feature=youtu.be eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG
1 · Reply
EddieHayes
EddieHayes Jul. 8 at 7:57 PM
$ARKG The accelerated uptrend has officially cooled off after a strong 3-week run that delivered nearly 30%. Momentum trades always face the same test: after the easy move is over, can buyers defend key levels and build the next setup? The bigger concern is not the pullback itself, but whether support zones across growth themes start failing one by one. If leadership continues rotating away, risk appetite could weaken quickly. For now, the battle is between profit-taking and whether long-term buyers step back in. Genomics, photonics, AI, and biotech are all competing for capital. The strongest themes will be the ones that keep attracting buyers when volatility rises.
0 · Reply
howardlindzon
howardlindzon Jul. 8 at 6:19 PM
$TWST largest holding of $ARKG
2 · Reply
madnessofcrowds
madnessofcrowds Jul. 8 at 3:28 PM
$ARKG bought 40.86
0 · Reply
Onestockatatime20
Onestockatatime20 Jul. 7 at 10:19 PM
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 7 at 10:13 PM
CMPS Stock Clocks Muted Gains But Analysts Back Psychedelic Drug’s Durability Ahead Of FDA Filing $CMPS $ARKG $IBB https://stocktwits.com/news/equity/markets/cmps-stock-clocks-muted-gains-but-analysts-back-psychedelic-drugs-durability-ahead-of-fda-filing/cZmlUsXR7Zn
0 · Reply
Woodman7
Woodman7 Jul. 14 at 10:12 AM
0 · Reply
degeneratetrader23
degeneratetrader23 Jul. 13 at 2:39 PM
$PSNL $ARKG, $TEM, and $NTRA are all red. This is mooning!
0 · Reply
madnessofcrowds
madnessofcrowds Jul. 10 at 8:42 PM
$ARKG locked in gains for about 25% of my position here. it's going much higher but wouldn't mind a cheaper entry.
0 · Reply
CactusPicksEm
CactusPicksEm Jul. 9 at 1:58 PM
$ARKG STO 8/21 50C for a 1.25 credit against my lot
0 · Reply
B2iDigital
B2iDigital Jul. 8 at 11:59 PM
eXoZymes (Nasdaq: $EXOZ ) makes its case for cell-free biomanufacturing, the approach it says sidesteps where whole-cell synthetic biology has repeatedly failed to scale. Whole-cell synthetic biology has a long record of stalling at scale. In a Webull webinar, eXoZymes Chief Commercial Officer Damien Perriman laid out why the company removed the cell from the equation entirely. eXoZymes Inc. is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/exozymes-1 "Engineered cells have become a boulevard of broken dreams on Wall Street, and eXoZymes found a way to navigate around this problem," said Damien Perryman, Chief Commercial Officer of eXoZymes. In the webinar, Perryman also covered: • Cells evolved to survive, not to manufacture, so whole-cell systems carry biological noise, toxicity limits, and regulatory complexity into production • eXoZymes isolates the enzymes, engineers them with AI, and runs them outside the cell to produce target molecules cleanly and at scale • The result behaves more like precision chemistry than a biological production system, inspired by biology's own catalysts Watch the full webinar: youtube.com/watch?v=OmH3TaaMT20&feature=youtu.be eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG
1 · Reply
EddieHayes
EddieHayes Jul. 8 at 7:57 PM
$ARKG The accelerated uptrend has officially cooled off after a strong 3-week run that delivered nearly 30%. Momentum trades always face the same test: after the easy move is over, can buyers defend key levels and build the next setup? The bigger concern is not the pullback itself, but whether support zones across growth themes start failing one by one. If leadership continues rotating away, risk appetite could weaken quickly. For now, the battle is between profit-taking and whether long-term buyers step back in. Genomics, photonics, AI, and biotech are all competing for capital. The strongest themes will be the ones that keep attracting buyers when volatility rises.
0 · Reply
howardlindzon
howardlindzon Jul. 8 at 6:19 PM
$TWST largest holding of $ARKG
2 · Reply
madnessofcrowds
madnessofcrowds Jul. 8 at 3:28 PM
$ARKG bought 40.86
0 · Reply
Onestockatatime20
Onestockatatime20 Jul. 7 at 10:19 PM
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 7 at 10:13 PM
CMPS Stock Clocks Muted Gains But Analysts Back Psychedelic Drug’s Durability Ahead Of FDA Filing $CMPS $ARKG $IBB https://stocktwits.com/news/equity/markets/cmps-stock-clocks-muted-gains-but-analysts-back-psychedelic-drugs-durability-ahead-of-fda-filing/cZmlUsXR7Zn
0 · Reply
madnessofcrowds
madnessofcrowds Jul. 7 at 8:06 PM
$ARKG nice consolidation day on lower volume
0 · Reply
Lakeview22
Lakeview22 Jul. 6 at 7:45 PM
$ARKG beast. Brick X Brick
0 · Reply
G_R_
G_R_ Jul. 6 at 3:05 PM
$CRSP Wound up tight, in a multi-year base, and above 25% short interest. 🤷‍♂️ $ARKG $IBB $XBI
0 · Reply
StockElementCorporation
StockElementCorporation Jul. 5 at 11:54 PM
Most traders only look at stocks that are going up. One of the biggest signs of institutional buying is relative strength—stocks making new highs while the overall market is chopping sideways. Those names continue to lead: Current names on my watch: $RDDT $HOOD $LMND $MRNA $ARKG TTWO , ABNB Follow for daily market education and watchlists before the move.
0 · Reply
Diefreeandsell
Diefreeandsell Jul. 5 at 9:14 PM
$XBI $IBRX $TNA $IBB $ARKG then of course there is that open gap for ibrx down that should get filled Monday as long as xbi continues it's breakout. Wed 4 Mar '26 9.59 → 9.8 closed Mondat July 6th🥁🥁😱 With a pre-mkt pr goes over 10.5 imo!😱😱✅
0 · Reply
ETAlpha
ETAlpha Jul. 5 at 9:11 PM
$ARKG is testing a major key level here.
0 · Reply
ssaudio
ssaudio Jul. 5 at 11:56 AM
$ARKG finally out!!!!!
1 · Reply
howardlindzon
howardlindzon Jul. 2 at 3:33 PM
$ARKG i’ll have to trade this again
2 · Reply
charleswindsor111
charleswindsor111 Jul. 2 at 2:17 PM
$ARKG and another 52 wk high... we'll see 50.00 in another week
0 · Reply
TraderRapp
TraderRapp Jul. 1 at 8:46 PM
$CAI when does Cathy Add Caris?! $ARKG
0 · Reply
charleswindsor111
charleswindsor111 Jul. 1 at 2:49 PM
$ARKG another 52 wk high...bigggg congrats to those that weathered the storm...💲💲💲💲
0 · Reply
Clargy
Clargy Jun. 30 at 11:31 PM
$ARKG If you haven't dug through the holdings list of even the most high-beta biotech ETFs, I highly recommend you do. AI-related breakthroughs and headlines are beginning to hit the tape for the healthcare industry. https://www.anthropic.com/news/claude-science-ai-workbench
0 · Reply